Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Appointment of Joint Broker

4th Apr 2016 07:00

RNS Number : 9722T
Quantum Pharma PLC
04 April 2016
 

Press Release

4 April 2016

 

 

 

 

 

Quantum Pharma Plc

(the "Company")

 

Appointment of Joint Broker

 

Quantum Pharma Plc (AIM: QP.), the growing, service-led niche pharmaceutical manufacturer, developer and supplier to the health and care sectors, is pleased to announce the appointment of N+1 Singer as the Company's Joint Broker, alongside Zeus Capital, with immediate effect.

 

- Ends -

 

For further information:

Quantum Pharma Plc

 

Andrew Scaife, Chief Executive Officer

Tel: +44 (0) 1207 279 404

Chris Rigg, Chief Financial Officer

www.quantumpharmaplc.com

 

 

Zeus Capital Limited

(Nominated Adviser & Joint Broker)

 

Andrew Jones / Nick Cowles / Jamie Peel

Tel: +44 (0) 20 3829 5000

Dominic Wilson / John Goold

www.zeuscapital.co.uk

 

 

N+1 Singer

(Joint Broker)

 

 

Aubrey Powell /James White/ Sandy Ritchie

Tel: +44 (0) 20 7496 3000

Nick Owen / Brough Ransom

 

www.n1singer.com

Media enquiries:

 

Buchanan

 

Henry Harrison-Topham / Sophie Cowles / Steph Watson

Tel: +44 (0) 20 7466 5000

[email protected]

www.buchanan.uk.com

 

Notes to Editors

 

Quantum Pharma is a service-led, niche pharmaceutical manufacturer, developer and supplier to the retail pharmacy, pharmaceutical wholesale, hospital, homecare and care home markets. Quantum Pharma operates through three divisions, offering a portfolio of innovative and complementary products and services.

 

Specials

Comprising four business units:

 

Quantum Pharmaceutical manufactures and supplies specials and special obtains for pharmacy chains, pharmaceutical wholesalers, hospitals and independent pharmacies in the UK.

 

UL Medicines sources and supplies unlicensed imported medicines, batch-made and bespoke specials to hospitals, community pharmacies and wholesalers in the UK and overseas.

 

NuPharm offers outsourced manufacture for solid and liquid dose batch-made specials and niche licensed medicines, product development as well as clinical trials product manufacture.

 

Quantum Aseptic Services manufactures aseptically prepared, sterile intravenous products, either individually, for named patients or in batches for supply to private and NHS hospitals and homecare patients.

 

Niche Pharmaceuticals

Comprising three business units:

 

Colonis® is a product development business, which takes niche pharmaceutical products through the regulatory pathway to achieve licensed and/or regulated status.

 

Lamda is a full-service contract development specialist with customers across Europe. It specialises in creating added-value products with distinct advantages for patients and health care providers. It also provides full services for the entire development chain - from inception to registration to post-approval, finished product supply and regulatory support.

 

PERN Consumer Products, owner of the Dermacool brand - a range of menthol in aqueous creams.

 

Medication Adherence

Comprising two business units:

 

Biodose® is a medicines delivery system that accommodates liquid and solid medication, supporting medicines administration and adherence, for patients, their carers and clinicians. Biodose Connect® - a telehealth version with the ability to remotely monitor medication adherence is in live testing.

 

Biodose Services® assembles and delivers pre-prepared medication regimes to care homes and homecare patients, incorporating Biodose® as appropriate.

 

For further information, please visit www.quantumpharmagroup.com.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCQFLFBQZFBBBV

Related Shares:

Quantum Pharma
FTSE 100 Latest
Value8,602.92
Change-2.06